Portal de Periódicos da CAPES

Real-life Data on First- and Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer With Abiraterone, Enzalutamide and Cabazitaxel – A multicentric Study From Portugal

2024; Elsevier BV; Volume: 22; Issue: 6 Linguagem: Inglês

10.1016/j.clgc.2024.102169

1938-0682

Francisco Botelho, Isaac Braga, Ricardo Leão, Frederico Teves, Jorge Dias, Filipe Rodrigues, Jorge Oliveira, I. Augusto, Catarina Portela, Joana Febra, Sandra Custódio, Patrícia Liu, Patrícia Gago, André Miranda, Carlos Silva, Luís Pacheco‐Figueiredo,

Prostate Cancer Diagnosis and Treatment

New drugs for metastatic castrate resistant prostate cancer (mCRPC) were approved, first in the pos-docetaxel and then in the pre-docetaxel setting. We aim to assess the real daily practice benefit of abiraterone (Abi), enzalutamide (Enz) and cabazitaxel (Cab) in patients with mCRPC, compare it with RCT results and compare Abi vs Enz.